Filter posts

Commercialization and Job Creation in the Biotechnology Sector

It’s tough presenting programs on technology transfer because so much has already been said that …

Beyond the ABCs of ADCs

The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody …

Resistance is Futile – SuperDrugs for SuperBugs

“MRSA’s kill 100,000 people a year, more than AIDS,” said Mark Leuchetenberger, President and CEO, …

Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice

Insights in to the molecular and genetic basis of disease are driving new product and …

Multiple Assets Diversify the Deal

With a recent surge in pharma companies collaborating earlier on with small biotech companies, discovery …

Public Exits and Virtual Biotechs - Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the …

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and …

BioFlorida Conference: Here's What You Missed

As I mentioned last week, BIO President & CEO James C. Greenwood kicked-off  this week’s …

Bioenergy Business Outlook Survey Measures Industry Confidence

Biofuels Digests’ Bioenergy Business Outlook Survey, co-sponsored by BIO, is a quarterly indicator of business …

BIO Investor Forum Company Snapshot: Protagonist Therapeutics

In our final Investor Forum Company Snapshot, we’ve profiled one of the Discovery Companies who …